BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries
BGLC is trading near its 52-week low of $1.92 (5.2% above the low).
Summary
BioNexus Gene Lab Corp reported a catastrophic 98.9% year-over-year decline in first-quarter 2026 revenue, falling to just $22.84K, alongside an EPS of ($0.23). While the net loss per share was reduced, the near-total collapse in revenue is a severe negative development. This earnings report significantly exacerbates the 'going concern' doubts previously highlighted in the company's last 10-K filing, which also noted substantial dilution. The company is attempting a business pivot towards CDMO services and commercializing VitaGuard™ MRD, but these results underscore immense operational challenges and liquidity pressures. Traders will closely monitor the company's ability to execute its new strategies and secure necessary financing, including potential digital asset or ATM financing, to avoid further financial distress.
At the time of this announcement, BGLC was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.92 to $15.60. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.